<article>Shanghai-based healthcare PE fund C-Bridge Capital has led a $20 million Series B funding round into Nuance Biotech while YuanMing Capital has invested $50 million into Series B into Adlai Nortye.</article>

Shanghai-based healthcare PE fund C-Bridge Capital has led a $20 million Series B funding round into Nuance Biotech while YuanMing Capital has invested $50 million into Series B into Adlai Nortye.
<h3>C Bridge Capital leads $20m round in Nuance Biotech</h3>
Shanghai-based healthcare PE fund <a href="https://www.dealstreetasia.com/tag/C-Bridge-Capital/">C-Bridge Capital</a> has led a $20 million Series B funding round into Nuance Biotech, a China-based specialty pharma company.
C-Bridge also supported $15 million to Nuance Biotech under a partnership between Nuance and US-based Pacira Pharmaceuticals.
Neo Zhang, Managing Director of C-Bridge Capital, will join the board of Nuance, the company said in an announcement.
“This investment represents a unique funding model for building a best-in-class pharmaceutical business in China,” according to Fu Wei, Chief Executive Officer of C-Bridge Capital.
C-Bridge Capital is a healthcare-dedicated private equity firm, focused on growth and late-stage investment opportunities. It has about $1.5 billion under management.
<h3>YuanMing Capital leads $50m Series B into Adlai Nortye</h3>
<a href="https://www.dealstreetasia.com/tag/YuanMing-Capital/">YuanMing Capital</a> and <a href="https://www.dealstreetasia.com/tag/Matrix-Partners-China/">Matrix Partners China</a> have led a Series B round of more than $50 million into Adlai Nortye, a listed Chinese science-led biopharma company, the China Money Network reported.
DT Capital Partners and Yahui Precision Medicine Fund also took part in the round.
Based in Hangzhou,  Adlai Nortye is a science-led biopharma company that is engaged in developing drugs for cancer and metabolic diseases. The company listed on the National Equities Exchange &amp; Quotations (NEEQ) last year.
YuanMing Capital is a healthcare fund focusing on China-US cross-border investments. Matrix Partners China, meanwhile, is affiliated with Matrix Partners, a US venture capital firm. The company focuses exclusively on investments in China.
Also Read: 
<a href="https://www.dealstreetasia.com/stories/china-healthcare-focused-pe-cbridge-raising-650m-third-fund-91320/">China’s healthcare-focused PE firm C-Bridge raising $650m third fund: Report</a>
<a style="color: #ff0000" href="https://www.dealstreetasia.com/stories/matrix-partners-fifth-fund-100332/">Matrix Partners China raises $750m for fifth venture capital fund </a>

Shanghai-based healthcare PE fund C-Bridge Capital has led a $20 million Series B funding round into Nuance Biotech while YuanMing Capital leads $50 million into Series B into Adlai Nortye. 

China Digest: C-Bridge invests in Nuance; YuanMing Capital backs Adlai Nortye

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

China Digest: C-Bridge invests in Nuance; YuanMing Capital backs Adlai Nortye

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief